Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNA–mRNA or Vector–mRNA COVID-19 VaccinesArticle Published on 2022-01-042022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] administer age booster vaccination Cambridge COVID-19 demonstrated dose health-care individual Infection infection with SARS-CoV-2 Mainz Mild symptom Moderna mRNA vaccine mRNA-based neutralization titer neutralization/neutralisation neutralizing responses Neutralizing titer neutralizing titers neutralizing/neutralising antibodies Oxford-AstraZeneca regimen regimens SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-infected individual single dose titer USA vaccination Vaccine vector vaccine were assessed were infected worker York [DOI] 10.3390/vaccines10010075 PMC 바로가기 [Article Type] Article
Rapid Decline in Vaccine-induced Anti-SARS-CoV-2 Antibody Titers 3 Months After Kidney Transplantation: A Case Series From Belgium신장 이식 3개월 후 백신 유도 Anti-SARS-CoV-2 항체 역가의 급격한 감소: 벨기에의 사례 시리즈Comment Published on 2022-01-012022-09-12 Journal: Transplantation [Category] SARS, 진단, [키워드] Belgium Decline Month Rapid Sery titer [DOI] 10.1097/TP.0000000000003963 PMC 바로가기 [Article Type] Comment
Immunogenicity and safety of SARS-CoV-2 vaccine with immunosuppressive agentsArticle Published on 2022-01-012022-11-15 Journal: Pediatrics international : official journal of the [Category] SARS, 진단, [키워드] acute respiratory syndrome Administered adolescents Adverse adverse event antibody Antibody titer Antibody titers Breakthrough infection children clinical effectiveness conducted coronavirus defined diagnosed disease domain dose enrolled evaluated event Factor FIVE immunogenic immunogenicity immunosuppressants immunosuppressive immunosuppressive agent Immunosuppressive agents Infection interquartile range median median age Messenger RNA mRNA mRNA vaccine non-recipient non-specific occurred Patient patients postvaccination Prospective Study recipient recipients rejection SARS-CoV-2 SARS-CoV-2 mRNA vaccine SARS-CoV-2 spike SARS-CoV-2 spike protein SARS-CoV-2 vaccine significantly lower solid organ transplant Solid organ transplant recipients SOT titer vaccination Vaccine Vaccine failure was measured were measured [DOI] 10.1111/ped.15331 PMC 바로가기
Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 InfectionArticle Published on 2021-12-312022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] administration antibody Antibody titer BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine conducted convalescent convalescent individual convalescent patient decay decrease determine dose faster had no individual individuals infection with COVID-19 infection with SARS-CoV-2 initial IQR less median of BNT162b2 Patient Pfizer-BioNTech mRNA vaccine Retrospective study SARS-CoV-2 SARS-CoV-2 IgG antibody SARS-COV-2 infection second vaccination service study period subject subjects subsequent the SARS-CoV-2 virus the vaccine thought threshold titer vaccinated individual vaccination Vaccine were measured [DOI] 10.3390/vaccines10010064 PMC 바로가기 [Article Type] Article
Seven-Month Analysis of Five SARS-CoV-2 Antibody Assay Results after ChAdOx1 nCoV-19 Vaccination: Significant Decrease in SARS-CoV-2 Antibody TiterArticle Published on 2021-12-302022-10-31 Journal: Diagnostics [Category] COVID-19, [키워드] Abbott acute respiratory syndrome antibodies antibody Antibody titer assay assays ChAdOx1 nCoV-19 change Complete contribute coronavirus Efficacy FIVE Genscript healthcare IgG investigated median positive rate Result Roche SARS-CoV-2 SARS-CoV-2 antibody SD Biosensor serum sample Seven Siemen Significant significantly titer vaccination Vaccination strategies Vaccination strategy Vaccine Viral load [DOI] 10.3390/diagnostics12010085 PMC 바로가기 [Article Type] Article
Immune Responses to SARS-CoV-2 Infection and Vaccination in Dialysis Patients and Kidney Transplant RecipientsArticle Published on 2021-12-212022-10-29 Journal: Microorganisms [Category] COVID-19, [키워드] acute respiratory syndrome anti-SARS-CoV-2 antibody antibodies AZD1222 BNT162b2 booster cellular Cellular immune response Cohort convalescent patient coronavirus COVID-19 COVID-19 vaccination criterion detectable dialysis elicited healthy individual healthy individuals humoral IgG titer immune immune response immune system immunization Immunosuppression independent risk factor initial interferon-γ Kidney disease kidney transplant Linear regression model medication mRNA-1273 Patient patient subgroup performed protection quantified reactivity receiving recipient recipients response Retrospective analysis SARS-CoV-2 separated Seroconversion seroconversion rate serological significantly lower titer Transplant vaccination [DOI] 10.3390/microorganisms10010004 PMC 바로가기 [Article Type] Article
Attenuation of Antibody Titers from 3 to 6 Months after the Second Dose of the BNT162b2 Vaccine Depends on Sex, with Age and Smoking Risk Factors for Lower Antibody Titers at 6 MonthsArticle Published on 2021-12-182022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] affected age Analysis analyzed Antibody titer Antibody titers attenuation blood sample BNT162b2 changes in Characteristics clinical epidemiology clinical variable collected coronavirus disease COVID-19 determine different time points enrolled Factor healthcare worker Japan Lower men Month mRNA vaccine participant Pfizer/BioNTech reduced SARS-CoV-2 second second dose Sex Sex difference significantly significantly lower smoking titer viral infection were used women [DOI] 10.3390/vaccines9121500 PMC 바로가기 [Article Type] Article
Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-UpAriano Irpino(캄파니아, 이탈리아) 시민의 SARS-CoV-2에 대한 체액 면역 반응의 지속성: 11.5개월 추적 관찰을 통한 종단 관찰 연구Observational Study Published on 2021-12-172022-09-11 Journal: Frontiers in Public Health [Category] MERS, SARS, 임상, 치료기술, 치료법, [키워드] 95% CI acute respiratory syndrome coronavirus 2 age Analysis anti-nuclear antibody Anti-nucleocapsid antibodies anti-nucleocapsid antibody anti-SARS-CoV-2 antibody Antibody Response association Asymptomatic Asymptomatic individuals BioRad Campania causative agent conducted coronavirus coronavirus disease COVID-19 deaths detectable enrolled Evidence evidence of females FIVE Immunity immunoassay Infection interquartile range Italy longitudinal Mass screening multiple logistic regression Multiple logistic regression analysis Neutralizing antibodies neutralizing antibody no evidence of observational study participant positive Presence Re-infection remained reported required respiratory respiratory syndrome coronavirus 2 response Roche SARS-CoV-2 SARS-CoV-2 antibody screened Screening Seroprevalence severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Sex significantly lower study cohort subject symptomatic symptomatic cases titer titers town Wuhan Wuhan, China [DOI] 10.3389/fpubh.2021.801609 PMC 바로가기 [Article Type] Observational Study
Association of the Serum Levels of the Nucleocapsid Antigen of SARS-CoV-2 With the Diagnosis, Disease Severity, and Antibody Titers in Patients With COVID-19: A Retrospective Cross-Sectional StudyMicrobiology Published on 2021-12-092022-10-31 Journal: Frontiers in Microbiology [Category] COVID-19, [키워드] Analysis Antibody titer Antigen automated chemiluminescence immunoassay clinical feature collected Coronavirus disease 2019 COVID-19 Cutoff cutoff value Diagnosis diagnosis of COVID-19 group IgG antibody titers Laboratory test Level moderate N antigen Non-COVID-19 nucleocapsid antigen Patient receiver operating characteristic SARS-CoV-2 SARS-CoV-2 nucleocapsid Sensitivity and specificity serum serum sample severe COVID-19 severity significant negative correlation significantly higher symptomatic patient the disease the patient the SARS-CoV-2 titer with mild disease [DOI] 10.3389/fmicb.2021.791489 PMC 바로가기 [Article Type] Microbiology
Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together밤라니비맙 단독 또는 밤라니비맙과 에테세비맙을 함께 투여받은 경증 또는 중등도 COVID-19 환자에서 SARS-CoV-2에 대한 내인성 항체 반응Clinical Trial Published on 2021-12-092022-09-11 Journal: Frontiers in Immunology [Category] SARS, 변종, 임상, 진단, 치료법, 치료제, [키워드] Administered antibodies Antibody Response Antibody titer Antibody titers antigenic B.1.351 bamlanivimab baseline Beta Beta variant binding breadth clinically Cohort collected correlated COVID-19 Day decrease develop domain Effect endogenous epitope Epitopes etesevimab evade Factor full-length Hospitalization humoral immune response in viral investigated longitudinal mAb mAbs Mild Moderate COVID-19 monoclonal antibody monotherapy Mortality multiplex mutant N-terminal domain Neutralization assay Neutralizing activity neutralizing monoclonal antibodies nucleocapsid protein Patient performed Placebo Received receiving recipient reduced reductions in response Result SARS-CoV-2 SARS-CoV-2 antigens SARS-COV-2 infection SARS-CoV-2 protein SARS-CoV-2 pseudovirus sera serology serum sample specificity subsequent titer titers treated Treatment Trial variant Viral Viral load [DOI] 10.3389/fimmu.2021.790469 PMC 바로가기 [Article Type] Clinical Trial